United Therapeutics CorpChange company Symbol lookupSelect an option...UTHR United Therapeutics CorpTOPS Top Ships IncBOLT Bolt Biotherapeutics IncACET Adicet Bio IncVCNX Vaccinex IncDYNT Dynatronics CorpALDX Aldeyra Therapeutics IncRVLP RVL Pharmaceuticals PLCMINDP Mind Technology IncVXRT Vaxart IncGo
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.
|
|
|
|
| |
UTHR's position in the Biotechnology industry
| Industry Peers | VRTX | REGN | |
|---|---|---|---|
Summary | |||
| Company Profile | United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso... | Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes... Go to VRTX summary | Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. The Company's commercialized... Go to REGN summary |
| 52-Week Change | VS. INDUSTRY | 18.76% | 18.96% |
| Market Cap | VS. INDUSTRY | $91.0B | $90.6B |
| Beta | VS. INDUSTRY | 0.5 | 0.2 |
| Dividend Yield | VS. INDUSTRY | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 27.25x | 22.06x |
| Data as of | |||
Fundamentals | |||
| Total Revenue (TTM) | VS. INDUSTRY | $9.5B | $12.7B |
| Profit Margin | VS. INDUSTRY | 35.40% | 33.93% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | 65.28% | 23.79% |
| Revenue Growth (TTM) | VS. INDUSTRY | 13.83% | -10.94% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.